financetom
Business
financetom
/
Business
/
Rossari Biotech files Rs 700-crore IPO papers with Sebi
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rossari Biotech files Rs 700-crore IPO papers with Sebi
Dec 18, 2019 10:16 AM

Rossari Biotech, speciality chemical maker with focus on home and personal care products, on Wednesday filed draft papers with capital markets regulator Sebi to float a Rs 700 crore initial public offering.

Share Market Live

NSE

The IPO comprises fresh issuance of shares to the tune of Rs 150 crore and sale of 1.05 crore equity shares by the company's promoters through offer-for-sale route, according to the draft prospectus filed with the Securities and Exchange Board of India (Sebi). Market sources said the IPO size will be worth Rs 700 crore.

The Mumbai-based company may consider a private placement of equity shares aggregating up to Rs 100 crore. If the pre-IPO placement is undertaken, the amount will be reduced from the fresh issue.

The company plans to utilise the net proceeds towards repayment or prepayment of certain indebtedness availed by Rossari Biotech, to fund working capital requirements and for general corporate purposes.Axis Capital and ICICI Securities are the merchant bankers for the share-sale.

The equity shares will be listed on the NSE and BSE. Rossari Biotech is a specialty chemicals manufacturing firm with focus on home and personal care, performance chemicals, textile specialty chemicals and animal health and nutrition products.

Apart from India, it has operations in 17 countries including Vietnam, Bangladesh and Mauritius.In the six months ended September 30, 2019, Rossari Biotech generated a revenue of Rs 279.76 crore and an EBITDA of Rs 50.62 crore.

First Published:Dec 18, 2019 7:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Scotiabank Notes Markets Are A Touch More Optimistic Early Wednesday
Scotiabank Notes Markets Are A Touch More Optimistic Early Wednesday
Mar 11, 2026
07:59 AM EST, 03/04/2026 (MT Newswires) -- The broad tone across global markets is a bit more positive early Wednesday, said Scotiabank. Oil prices are up by either side of 1% for WTI and Brent, but slight optimism shines elsewhere, noted the bank. United States equity futures are marginally positive, TSX futures more so, and European equity cash markets are...
Fennec Pharmaceuticals Collaborates With TGH Cancer Institute for Pedmark Study
Fennec Pharmaceuticals Collaborates With TGH Cancer Institute for Pedmark Study
Mar 11, 2026
07:59 AM EST, 03/04/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) said Wednesday that the Tampa General Hospital, or TGH, Cancer Institute is launching a study on the real-world clinical utility of Pedmark in reducing the risk of ototoxicity in adolescent, young adult and adult cancer patients receiving cisplatin-based treatment. Pedmark, or sodium thiosulfate injection, is approved in the...
Form 8.3
Form 8.3
Mar 11, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 11, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved